<DOC>
	<DOC>NCT00380965</DOC>
	<brief_summary>This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.</brief_summary>
	<brief_title>Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy</brief_title>
	<detailed_description>To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain. This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients diagnosed with chemotherapyinduced neuropathic pain. Chronic daily pain present for at least 2 months. On stable analgesic regimen for one month. Baseline pain score greater than 40mm on a VAS. Hypersensitivity to compounds in study drug or similar drugs Pregnant or lactating females Drug or alcohol abuse Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Chemotherapy-induced</keyword>
	<keyword>neuropathy</keyword>
	<keyword>cancer</keyword>
</DOC>